Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Leiomyosarcoma × niraparib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Ovarian Neoplasms 59 Breast Neoplasms 18 Prostatic Neoplasms 14 Neoplasms 14 Fallopian Tube Neoplasms 13 Neoplasm Metastasis 8 Pancreatic Neoplasms 7 Glioblastoma 7 Endometrial Neoplasms 6 Carcinoma, Ovarian Epithelial 5 Triple Negative Breast Neoplasms 4 Lung Neoplasms 4 Glioma 4 Squamous Cell Carcinoma of Head and Neck 3 Small Cell Lung Carcinoma 3 Recurrence 3 Melanoma 3 Head and Neck Neoplasms 3 Cholangiocarcinoma 3 Uterine Cervical Neoplasms 2 Solid Tumor 2 Sarcoma 2 Prostatic Neoplasms, Castration-Resistant 2 Mesothelioma, Malignant 2 Mesothelioma 2 Esophageal Neoplasms 2 Colorectal Neoplasms 2 Carcinoma, Renal Cell 2 Brain Neoplasms 2 Biliary Tract Neoplasms 2

Interventions

Doxorubicin 20 Gemcitabine 15 Trabectedin 11 Ifosfamide 10 Docetaxel 10 Radiotherapy 8 Dacarbazine 7 pazopanib 6 Temozolomide 4 Biopsy 4 Sunitinib 3 Specimen Handling 3 Sorafenib 3 Nivolumab 3 Filgrastim 3 pembrolizumab 2 pegfilgrastim 2 liposomal doxorubicin 2 eribulin 2 cixutumumab 2 brostallicin 2 belinostat 2 avelumab 2 Surgical Procedures, Operative 2 Radiotherapy, Conformal 2 Radiation 2 PTC596 2 Letrozole 2 Epirubicin 2 Bevacizumab 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05174455 2023-09-18

Niraparib for the Treatment of Leiomyosarcoma

Ohio State University Comprehensive Cancer Center

Phase 2 Withdrawn

Leiomyosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡